December 8 at 6 am PT/9 am ET

In today's era of disruption, arguably no US agency is facing greater challenges than the FDA. The unprecedented demands of the COVID-19 pandemic, the need to engage underserved communities and better recognize social determinants of health, the rise of digital health, the emergence of cell and gene therapies—these are but a few of the trends forcing the FDA to create innovative ways to regulate and oversee medical products. For the FDA to meet its public health mission requires that the agency be more flexible than ever before. Former FDA commissioners will discuss the importance of transparency and trust, the politicization of the agency, lessons learned from COVID-19, and how the agency can stay true to its mission in this age of upheaval.
 

Speakers

Robert Califf
Head of Clinical Policy and Strategy, Verily Life Sciences and Google Health; former Commissioner, US Food and Drug Administration

Margaret Hamburg
former Commissioner, US Food and Drug Administration

Mark McClellan
Director, Duke-Robert J. Margolis, MD Center for Health Policy and Robert J. Margolis, MD Professor of Business, Medicine, and Policy, Duke University; former Commissioner, US Food and Drug Administration
 

Moderator

Meg Tirrell
Biotech and Pharma Reporter, CNBC